Archives of Neuroscience

Published by: Kowsar

SCN1A and ABCB1 Polymorphisms in Epilepsy

Mojgan Hosseini 1 , * , Ahmad Ebrahimi 2 , Massoud Houshmand 3 , Sirous Zainali 4 , Seyed Hassan Tonekaboni 5 and Mehdi Moghaddasi 6
Authors Information
1 Department Science, Islamshahr Branch, Islamic Azad University, Tehran, Iran
2 Parseh Medical Genetic Center, Tehran, Iran
3 National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
4 Kawsar Human Genetic Research Center, Tehran, Iran
5 Shaheed Beheshti University of Medical Sciences, Tehran, Iran
6 Iran University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Neuroscience: January 2018, 5 (1); e59383
  • Published Online: January 8, 2018
  • Article Type: Research Article
  • Received: January 29, 2017
  • Revised: September 10, 2017
  • Accepted: November 26, 2017
  • DOI: 10.5812/archneurosci.59383

To Cite: Hosseini M, Ebrahimi A, Houshmand M, Zainali S, Tonekaboni S H, et al. SCN1A and ABCB1 Polymorphisms in Epilepsy, Arch Neurosci. 2018 ; 5(1):e59383. doi: 10.5812/archneurosci.59383.

Abstract
Copyright © 2018, Archives of Neuroscience. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnote
References
  • 1. Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain. 2006;129(Pt 1):18-35. doi: 10.1093/brain/awh682. [PubMed: 16317026].
  • 2. Ragsdale DS, Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res Brain Res Rev. 1998;26(1):16-28. [PubMed: 9600622].
  • 3. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol. 2008;66(2):304-7. doi: 10.1111/j.1365-2125.2008.03203.x. [PubMed: 18489610].
  • 4. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br J Clin Pharmacol. 2009;68(2):214-20. doi: 10.1111/j.1365-2125.2009.03437.x. [PubMed: 19694741].
  • 5. Ohmori I, Kahlig KM, Rhodes TH, Wang DW, George AJ. Nonfunctional SCN1A is common in severe myoclonic epilepsy of infancy. Epilepsia. 2006;47(10):1636-42. doi: 10.1111/j.1528-1167.2006.00643.x. [PubMed: 17054685].
  • 6. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005;102(15):5507-12. doi: 10.1073/pnas.0407346102. [PubMed: 15805193].
  • 7. Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009;50(1):1-23. doi: 10.1111/j.1528-1167.2008.01716.x. [PubMed: 18627414].
  • 8. Vahab SA, Sen S, Ravindran N, Mony S, Mathew A, Vijayan N, et al. Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug Metab Pharmacokinet. 2009;24(3):255-60. [PubMed: 19571437].
  • 9. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473-8. doi: 10.1073/pnas.050585397. [PubMed: 10716719].
  • 10. Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res. 2009;85(1):89-95. doi: 10.1016/j.eplepsyres.2009.02.014. [PubMed: 19303743].
  • 11. Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM, et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet. 2007;80(5):876-83. doi: 10.1086/516650. [PubMed: 17436242].
  • 12. Engel JJ. Report of the ILAE classification core group. Epilepsia. 2006;47(9):1558-68. doi: 10.1111/j.1528-1167.2006.00215.x. [PubMed: 16981873].
  • 13. Ebrahimi A, Houshmand M, Tonekaboni SH, Fallah Mahboob Passand MS, Zainali S, Moghadasi M. Two novel mutations in SCN1A gene in Iranian patients with epilepsy. Arch Med Res. 2010;41(3):207-14. doi: 10.1016/j.arcmed.2010.04.007. [PubMed: 20682179].
  • 14. Depondt C. The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol. 2006;10(2):57-65. doi: 10.1016/j.ejpn.2005.11.009. [PubMed: 16531088].
  • 15. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348(15):1442-8. doi: 10.1056/NEJMoa021986. [PubMed: 12686700].
  • 16. Farjadian S, Ota M, Inoko H, Ghaderi A. The genetic relationship among Iranian ethnic groups: an anthropological view based on HLA class II gene polymorphism. Mol Biol Rep. 2009;36(7):1943-50. doi: 10.1007/s11033-008-9403-4. [PubMed: 18979226].
  • 17. Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538-49. doi: 10.1056/NEJMra020526. [PubMed: 12571262].
  • 18. Mann MW, Pons G. Various pharmacogenetic aspects of antiepileptic drug therapy: a review. CNS Drugs. 2007;21(2):143-64. [PubMed: 17284096].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments